4,5-Dihydroxypyrimidine Carboxamides and N-Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species
Journal of Medicinal Chemistry2006Vol. 49(23), pp. 6646–6649
Citations Over TimeTop 10% of 2006 papers
Vincenzo Summa, Alessia Petrocchi, Victor G. Matassa, Cristina Gardelli, Ester Muraglia, Michael Rowley, Odalys Gonzalez Paz, Ralph Laufer, Edith Monteagudo, Paola Pace
Abstract
The dihydroxypyrimidine carboxamide 4a was discovered as a potent and selective HIV integrase strand transfer inhibitor. The optimization of physicochemical properties, pharmacokinetic profiles, and potency led to the identification of 13 in the dihydroxypyrimidine series and 18 in the N-methylpyrimidinone series having low nanomolar activity in the cellular HIV spread assay in the presence of 50% normal human serum and very good pharmacokinetics in preclinical species.
Related Papers
- Characterization and structural analysis of HIV-1 integrase conservation.(2009)
- → Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy(2010)73 cited
- → Integrase inhibitors in the treatment of HIV-1 infection(2010)56 cited
- → Structural-Functional Analysis of 2,1,3-Benzoxadiazoles and Their N-oxides As HIV-1 Integrase Inhibitors(2013)22 cited
- → Synthesis and HIV-1 Integrase Inhibition Activity of some N-Arylindoles(2008)46 cited